Robotic Workstation Prints 2.4 Million Microarrays per Year
By LabMedica International staff writers Posted on 31 Dec 2009 |
Advance in the speed and efficiency of manufacturing microarrays allows highly precise printing of as many as 2.4 million microarrays per year with a single robotic workstation. The microarrays are tiny glass substrates that contain rows and columns of printed spots used for molecular diagnostics and scientific research.
The technological breakthrough was made by Arrayit Corporation (Sunnyvale, CA, USA); its current capacity is 640,000 microarrays per instrument annually. The enhanced automated microarray printing bandwidth increases company's competitiveness in the diagnostics marketplace.
Arrayit executive vice president and cofounder Todd Martinsky stated, "This technological advance represents an engineering tour de force that combines our expertise in laboratory automation, linear drive robotics, micromachining, surface chemistry and contact printing. Leveraging our core tech competencies and patented contact printing platform in this manner should further enhance our competitive differentiation in the diagnostics market."
Arrayit Corporation discovers, develops, and manufactures life science technologies and consumables for disease prevention, treatment, and cure. The company is currently developing early stage definitive diagnostic tests for ovarian cancer, Parkinson's disease, influenza A virus (H1N1) and other illnesses.
Related Links:
Arrayit Corporation
The technological breakthrough was made by Arrayit Corporation (Sunnyvale, CA, USA); its current capacity is 640,000 microarrays per instrument annually. The enhanced automated microarray printing bandwidth increases company's competitiveness in the diagnostics marketplace.
Arrayit executive vice president and cofounder Todd Martinsky stated, "This technological advance represents an engineering tour de force that combines our expertise in laboratory automation, linear drive robotics, micromachining, surface chemistry and contact printing. Leveraging our core tech competencies and patented contact printing platform in this manner should further enhance our competitive differentiation in the diagnostics market."
Arrayit Corporation discovers, develops, and manufactures life science technologies and consumables for disease prevention, treatment, and cure. The company is currently developing early stage definitive diagnostic tests for ovarian cancer, Parkinson's disease, influenza A virus (H1N1) and other illnesses.
Related Links:
Arrayit Corporation
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans